Pyrroloquinoline quinone promotes human mesenchymal stem cell-derived mitochondria to improve premature ovarian insufficiency in mice through the SIRT1/ATM/p53 pathway
The mechanism of action for MSC-Mito therapy in conjunction with PQQ in chemotherapy-induced POI is as follows: PQQ facilitates MSC-Mito proliferation in cells and, in synergy with MSC-Mito, mitigates the elevated ROS levels induced by chemotherapy, thereby reducing mitochondrial damage. Simultaneously, this enhances the expression of SIRT1, upregulates TERF2 to promote DNA damage repair, suppresses ATM/p53 pathway activation, and reduces cellular apoptosis. Furthermore, SIRT1 upregulates PGC-1α, promoting mitochondrial biogenesis and maintaining cellular homeostasis
Publication
Pyrroloquinoline quinone promotes human mesenchymal stem cell-derived mitochondria to improve premature ovarian insufficiency in mice through the SIRT1/ATM/p53 pathway (2024) Shengjie Liu, et al. Stem Cell Res Ther. 2024;15(NA). Figure: F5.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | ATM | ATM | ncbigene_symbol | ATM | 472 |
| Homo sapiens | Primates | p53 | P53 | ncbigene_synonym | TP53 | 7157 |
| Homo sapiens | Primates | p53 | P53 | famplex_relations | TP63 | 8626 |
| Homo sapiens | Primates | p53 | P53 | famplex_relations | TP73 | 7161 |
| Homo sapiens | Primates | CTX | CTX | ncbigene_synonym | CYP27A1 | 1593 |
| Homo sapiens | Primates | SIRT1 | SIRT1 | ncbigene_symbol | SIRT1 | 23411 |
| Homo sapiens | Primates | PGC-1a | PGC-1A | ncbigene_synonym | PPARGC1A | 10891 |
| Homo sapiens | Primates | TERF2 | TERF2 | ncbigene_symbol | TERF2 | 7014 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| CTX | CTX | (2R,2'R,3a'S,4S,4a'R,5'S,6'S,6a'S,9'S,10'S,10a'R,11a'S,12a'R,13a'S,14a'R,15a'S,17'Z,19a'R,20a'S,22a'R,23a'S,24'R,24a'R,26'R,29a'S,30a'R,31a'S,32a'R,34a'S,35a'R,37'R,37a'S,38a'R)-26'-[(1E,3S)-3,4-dihydroxybut-1-en-1-yl]-2',5',9',10',37a'-pentamethyl-1',3',3a',4,4a',5,5',6',6a',9',10',10a',11a',12',12a',13a',14',14a',15a',16',19',19a',20a',22a',23a',24',24a',26',29',29a',30a',31',31a',32a',34a',35a',36',37',37a',38a'-tetracontahydro-2'H,3H-spiro[furan-2,8'-oxepino[2'''',3'''':5''',6''']pyrano[2''',3''':5'',6'']pyrano[2'',3'':6',7']oxepino[2',3':6,7]oxepino[3,2-b]pyrano[2''''',3''''':6'''',7'''']oxepino[2'''',3'''':5''',6''']pyrano[2''',3''':7'',8'']oxocino[2'',3'':5',6']pyrano[2',3':6,7]oxepino[2,3-h]oxonine]-4,6',24',37'-tetrol | chebi:36467 | |
| ROS | ROS | chebi:26523 | ||
| Pyrroloquinoline quinone | pyrroloquinoline quinone | 4,5-dioxo-4,5-dihydro-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylate | chebi:58442 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|